Fresenius SE KGaA (XSWX:FRE) YoY EBITDA Growth: -12.62% (As of Mar. 2026)


XSWX:FRE Fresenius SE & Co KGaA XSWX:FRE
69 GF Score
Price CHF39.27
GF Value CHF33.89
! 5 Warning Signs
View Full Analysis

What is Fresenius SE KGaA YoY EBITDA Growth?

Fresenius SE KGaA XSWX:FRE 69 YoY EBITDA Growth is -12.62% as of Mar. 2026. GuruFocus rates XSWX:FRE with a GF Score™ of 69/100 and a GF Value™ of CHF33.89. The stock has 5 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Fresenius SE KGaA's YoY EBITDA Growth for the quarter that ended in Mar. 2026 was -12.62%.

Fresenius SE KGaA's EBITDA per Share for the three months ended in Mar. 2026 was CHF1.41.

Fresenius SE KGaA YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Fresenius SE KGaA's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fresenius SE KGaA YoY EBITDA Growth Chart

Fresenius SE KGaA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.88 -57.94 -17.29 27.73 8.01

Fresenius SE KGaA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.60 -9.50 -1.03 27.67 -12.62
XSWX:FRE
69GF Score
Fresenius SE & Co KGaA XSWX:FRE
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fresenius SE KGaA YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Fresenius SE KGaA's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(6.218-5.757)/ | 5.757 |
=8.01 %

Fresenius SE KGaA's YoY EBITDA Growth for the quarter that ended in Mar. 2026 is calculated as:

YoY EBITDA Growth (Q: Mar. 2026 )
=(EBITDA per Share (Q: Mar. 2026 )-EBITDA per Share (Q: Mar. 2025 )) / | EBITDA per Share (Q: Mar. 2025 )) |
=(1.412-1.616)/ | 1.616 |
=-12.62 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of -12.62% mean?
Fresenius SE KGaA (XSWX:FRE) has a YoY EBITDA Growth of -12.62% as of Mar. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Fresenius SE KGaA and its competitors.
Is Fresenius SE KGaA's YoY EBITDA Growth too high?
Fresenius SE KGaA's current YoY EBITDA Growth is -12.62%. Overall, Fresenius SE KGaA has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does Fresenius SE KGaA's YoY EBITDA Growth compare to HCA and THC?
Fresenius SE KGaA's YoY EBITDA Growth of -12.62% can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Healthcare Providers & Services company?
A good YoY EBITDA Growth depends on the Healthcare Providers & Services industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Fresenius SE KGaA and its competitors. Fresenius SE KGaA's current YoY EBITDA Growth is -12.62%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fresenius SE KGaA stock overvalued right now?
Fresenius SE KGaA (XSWX:FRE) has a current YoY EBITDA Growth of -12.62%. The stock's GF Value™ is CHF33.89, compared to a current price of CHF39.27 — trading 15.9% above its estimated fair value. The current YoY EBITDA Growth is -12.62%. Fresenius SE KGaA's overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Fresenius SE KGaA (XSWX:FRE), the current YoY EBITDA Growth is -12.62% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fresenius SE KGaA (XSWX:FRE) Overvalued in 2026?

Based on GuruFocus' analysis, Fresenius SE KGaA stock appears to be overvalued. The current stock price of CHF39.27 is trading 15.9% above its estimated GF Value™ of CHF33.89.

Key valuation signals for XSWX:FRE:

  • YoY EBITDA Growth: -12.62%
  • GF Value™: CHF33.89 vs. price of CHF39.27 (15.9% above fair value)
  • GF Score™: 69/100 with 5 warning signs

No single metric tells the full story. See the XSWX:FRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fresenius SE KGaA Business Description

Address Else-Kroener-Strasse 1, Bad Homburg, HE, DEU, 61352
Fresenius is a healthcare holding company based in Germany. The company owns a minority stake in dialysis service provider and equipment manufacturer Fresenius Medical Care. The Kabi segment manufactures intravenous drugs, nutrition products, infusion and transfusion therapies, and related pumps. The Helios segment operates private hospitals primarily in Germany and Spain.
69GF Score

Get the complete analysis for XSWX:FRE

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF39.27
Price
CHF33.89
GF Value